With elite scientists and years of experience, Creative Biolabs can provide highly tailored service for CellRapeutics™ Chimeric Antigen Receptor (CAR) construction. The CAR modified immune cells therapy can attack cancer via genetic engineering different types of immune cells, such as T cell and natural killer cell. Creative Biolabs has a unique, unparalleled and all-round CellRapeutics™ CAR construction and production platform which can satisfy various customers' needs.
CAR consists of a single chain antibody (scFv) domain, a transmembrane domain and cytoplasmic signaling domains. With years of experience in research, our scientists have successfully performed CAR expression in a variety of immune cell types such as T-cells and NK cells based on Lentiviral vector. The lentiviral vector, with its high efficiency in cell transduction for both dividing and nondividing cells, and long-term and stable protein expression ability, has much wider application range than other vectors. CAR genetically modified specifically CAR-T cells or CAR-NK cells can target tumor-associated antigens and kill cancer cells through antigen-specific but non-MHC restricted, directed cell-mediated cytotoxicity. As an immune-therapeutic intervention strategy, CAR modified immune cells therapy has shown unparalleled promise for treating a variety of malignant conditions.
As a reliable partner in CAR construction field, Creative Biolabs has established a solid platform which can provide unmatched services with the highest quality.
Copyright © 2007 - 2016 Creative Biolabs. All Rights Reserved